报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
---|---|---|---|---|---|---|---|---|
2024-09-30 | 77.84% | -4.81% | -0.71% | 22/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
2024-06-30 | 78.4% | -4.67% | 0.45% | 21/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
2024-03-31 | 78.05% | -3.63% | -2.76% | 22/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
2023-12-31 | 80.27% | -1.67% | -1.85% | 24/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
2023-09-30 | 81.78% | -0.61% | -0.55% | 16/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
2023-06-30 | 82.23% | -0.12% | 1.54% | 19/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
2023-03-31 | 80.99% | -1.77% | -0.79% | 22/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
2022-12-31 | 81.63% | -2.41% | -0.79% | 19/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
2022-09-30 | 82.28% | -1.64% | -0.06% | 17/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
2022-06-30 | 82.33% | -1.94% | -0.13% | 21/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
2022-03-31 | 82.44% | 2% | -1.44% | 19/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
2021-12-31 | 83.65% | -1.2% | -0.01% | 23/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
2021-09-30 | 83.66% | 2% | -0.36% | 17/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
2021-06-30 | 83.96% | -0.54% | -0.83% | 17/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
2020-12-31 | 84.66% | -1.18% | 0.29% | 15/160 | -143.08% | 艾力斯 | 99.4% | 行业排名> |
2020-06-30 | 84.42% | -0.04% | -1.47% | 12/160 | 54.32% | 首药控股 | 99.94% | 行业排名> |
2019-12-31 | 85.68% | -0.93% | -0.93% | 11/160 | -1204.25% | 泽璟制药 | 99.96% | 行业排名> |
2018-12-31 | 86.48% | -0.93% | -0.93% | 11/160 | -205.91% | 微芯生物 | 95.14% | 行业排名> |
2017-12-31 | 87.29% | 2% | 3.36% | 7/160 | 52.58% | 多瑞医药 | 95.59% | 行业排名> |
2015-06-30 | 84.45% | 2% | 2% | 3/160 | 45.36% | 微芯生物 | 95.81% | 行业排名> |